Telomir seeks FDA approval for Telomir-1 to treat breast cancer

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.

Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial of Telomir-1 as an oral single agent for patients with advanced or metastatic TNBC.

Telomir-Zn is described as a first-in-class metal-modulating epigenetic agent designed to restore transcriptional control in tumour cells.

According to to a company release, Telomir said that IND-enabling good laboratory practice (GLP) safety studies reported no treatment-related or dose-limiting toxicities and favourable cardiovascular, respiratory, and phototoxicity profiles. Systemic exposure was consistent, and pharmacokinetics were predictable.

The Phase I segment of the trial will use a standard three-plus-three dose-escalation design to evaluate the safety, tolerability, dose-limiting toxicities, and recommended Phase II dose.

Phase II will use a Simon two-stage design to assess preliminary antitumour activity through objective response rate as the primary endpoint, along with duration of response, progression-free survival, and continued safety evaluation.

Telomir Pharmaceuticals has submitted manuscripts to peer-reviewed journals and plans to present its findings at scientific conferences, including the American Association for Cancer Research (AACR) annual meeting in 2026.

Telomir Pharmaceuticals CEO Erez Aminov said: “This IND submission marks a critical transition from preclinical proof-of-concept to clinical development for Telomir-Zn.

“TNBC patients with advanced disease have few durable treatment options, and we believe that targeting the biological mechanisms driving treatment resistance, specifically iron-dependent epigenetic dysregulation, represents a differentiated and scientifically grounded approach. We look forward to advancing this programme into the clinic.”

The post Telomir seeks FDA approval for Telomir-1 to treat breast cancer appeared first on Pharmaceutical Business review.